SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid escalating US-Israel-Iran tensions, polarizing community sentiment between expectations of a significant market downturn and calls to 'buy the dip' based on historical geopolitical recoveries, alongside active debate over oil market stability and market manipulation.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating Middle East tensions, following drone strikes on Saudi oil facilities and effective restrictions in the Strait of Hormuz, are sending crude prices soaring, leading the community to anticipate a significant short squeeze and parabolic rally for low-float energy play Indonesia Energy Corp.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is trending amidst surging oil prices driven by escalating Middle East tensions, including drone strikes on Saudi oil infrastructure and threats to the Strait of Hormuz. The community is heavily focused on potential short squeezes and the stock's low float, positioning it as a leading play in the volatile energy sector.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as escalating geopolitical tensions involving the US, Israel, and Iran spark intense community debate, with many divided between anticipating a significant market correction and a "buy the dip" mentality, while concerns over rising oil prices and market manipulation remain key talking points.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating geopolitical tensions in the Middle East, with reports of US-Israeli strikes on Iran and retaliatory attacks leading to significant disruptions and increased war risk premiums for shipping through the critical Strait of Hormuz. The community is actively discussing the potential for a substantial oil price spike and the broader implications for global supply, overshadowing OPEC+'s modest output increase.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as escalating Middle East tensions threaten global LNG supply routes like the Strait of Hormuz, leading to anticipation of surging gas prices and a significant short squeeze. The community highlights VG's strong Q4 performance and rapidly expanding capacity, believing the company is exceptionally positioned to capitalize on current market dynamics despite conservative future guidance.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is experiencing a surge of interest after activist investor Elliott Management disclosed a substantial stake, advocating for governance and strategic overhauls to improve the company's lagging performance against rivals. The community is buzzing with optimism for a potential turnaround and a new CEO's impact, despite past frustrations and concerns over broader market conditions.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil (XOM) is trending as escalating geopolitical tensions in the Middle East, particularly around potential disruptions to oil flows through the Strait of Hormuz, are driving a significant surge in crude prices across global markets. The community is actively debating whether this reflects a sustainable surge for energy stocks, with many buying on expectations of higher oil prices, while others anticipate a temporary spike followed by a pullback.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

QURE is experiencing extreme volatility following controversial FDA comments and feedback indicating its AMT-130 data may not support an accelerated approval BLA, sparking a heated community debate about the remarks' true target and the unpredictable regulatory path for its Huntington's disease gene therapy.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is rallying on an earnings beat and highly optimistic revenue guidance, fueled by surging demand for its 800G optical transceivers critical for AI data centers. The community is sharply divided, with bulls highlighting its essential role in AI infrastructure and aggressive growth outlook, while skeptics point to historical over-guidance and concerns over a recent stock offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Senseis Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893...

Small Cap Stocks To Add to Your Watchlist - February 18th

Rackspace Technology, Direxion Daily PLTR Bear 1X Shares, Spring Valley Acquisition, Direxion Daily MU Bull 2X Shares, Sensei Biotherapeutics, Inflection Point Acquisition Corp. II, and Direxion...

<ul class="summary-bullets"><li>The company also secured a private placement financing worth around $200 million.</li><li>Sensei Biotherapeutics plans to use the majority of the proceeds to advance PIKTOR.</li><li>Remaining funds will be used for the development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.</li></ul>Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.<a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> rose to its highest since May 2024 and recorded its biggest-ever intraday gains. Trading in the stock was twice halted after the opening bell, according to Nasdaq data.The acquisition adds Faeth’s lead investigational therapy, PIKTOR, an all-oral drug combination that targets tumor metabolism and blocks multiple points in the PI3K/AKT/mTOR pathway, a critical cell signaling system that regulates cell survival, growth, and division.“In the PI3K pathway, the field has repeatedly run into the same constraint. Single-node inhibitors force a tradeoff between efficacy and tolerability. PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability,” said Anand Parikh, Co-founder of Faeth Therapeutics and the new COO and director of Sensei.<h2 class="st-heading-2">$200 Million Private Placement</h2>Sensei Biotherapeutics also secured private placement financing, worth about $200 million. The company plans to use most of the capital to advance PIKTOR, including topline results from an ongoing Phase 2 trial in second-line advanced endometrial cancer and the launch of a Phase 1b study in HR+/HER2- advanced breast cancer, both anticipated by the end of 2026.Remaining funds will support general corporate initiatives and the continued development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.The private placement attracted participation from B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, and Vivo Capital, among other life sciences funds and institutional investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish,’ amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SNSE_jpg_53f7157d12.webp" alt="SNSE.jpg">One user expects the stock to “go up big” if it holds above the $25.4 to $25.5 support. It is currently trading at around $28.<stembedurl>https://stocktwits.com/brewstocks123/message/645236001</stembedurl>Another user expects the stock to climb to $44 by the end of the session.<stembedurl>https://stocktwits.com/FreyBentos/message/645238839</stembedurl>The stock has gained around 160% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rxt-stock-soars-pre-market-palantir-connection/cZR0r6BR4vX">RXT Stock Soared 275% Today – What’s The Connection&nbsp;With Palantir?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Representative image of a trending stock chart.

 SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition

Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.

Equity

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Sensei Biotherapeutics Stock Soars 230% After Faeth Deal

SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pipeline targeting cancer.read more...

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (Faeth), a clinical-stage biotechnology company developing multi-node therapies that target...

Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 3,105 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 3,105 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average...

James Peyer Sells 5,000 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 5,000 shares of the firm's stock in a transaction on Thursday, December 4th. The shares were sold at an...

What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After Hours Jump?

Sensei Biotherapeutics surged in after-hours trading Thursday, with strong recent gains and ongoing shareholder activity drawing attention.read more...

<ul class="summary-bullets"><li>The company stated that it anticipates reducing its workforce to conserve cash as part of its strategic review.</li><li>The company said that it decided not to initiate a new clinical study of Solnerstotug in cancer patients after reviewing “future funding needs and current capital markets environment.” &nbsp;</li></ul>Sensei Biotherapeutics, Inc. (SNSE) on Thursday said that its Board of Directors has determined to discontinue development of its lead product candidate, Solnerstotug, and initiate a comprehensive review of strategic alternatives.The Board came to the decision after extensive consideration, it said. The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/30/3177470/0/en/Sensei-Biotherapeutics-Announces-Initiation-of-Strategic-Review-to-Maximize-Shareholder-Value.html">said</a>. Further, there is no assurance that the review will result in a transaction, the company added.<h2 class="st-heading-2">Workforce Reduction Plans</h2>The company stated that it anticipates reducing its workforce to conserve cash as part of its strategic review. Details of the layoffs will be announced separately, the company said.Sensei Biotherapeutics, however, plans to retain a small team of employees to assist in the strategic review process and to manage a smooth transition of developmental activities. &nbsp;The company said that it decided not to initiate a new clinical study of Solnerstotug in cancer patients after reviewing “future funding needs and current capital markets environment.” The drug had demonstrated clinical activity in previous trials.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company rallied 5% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.SNSE stock is up 5% this year and down by 10% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, Sensei said.

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei said.


Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$30.50
Prev Close	$30.22
Open	$29.03
Dividend Yield	0.00%
50-Day Moving Average	$13.20
Beta	0.81
Avg. Volume	103,199.30
PE Ratio	-1.43

52-Week High	$36.76
52-Week Low	$5.00
Market Capitalization	$38.47M
EPS (Annual)	-$24.01
Price to Book	1.41
Revenue Per Employee	$0.00

SNSE
Sensei Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SNSE News

SNSESensei Biotherapeutics Inc